Scroll

desflurane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
halogenated compounds used as general inhalation anaesthetics	811	57041-67-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: Difluoromethyl 1,2,2,2-tetrafluoroethyl ether desflurane	A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia. Molecular weight: 168.04 Formula: C3H2F6O CLOGP: 1.51 LIPINSKI: 0 HAC: 1 HDO: 0 TPSA: 9.23 ALOGS: -1.68 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
desflurane

A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia.

Molecular weight: 168.04
Formula: C3H2F6O
CLOGP: 1.51
LIPINSKI: 0
HAC: 1
HDO: 0
TPSA: 9.23
ALOGS: -1.68
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 18, 1992	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Procedural hypotension	93.87	40.40	17	1328	1173	63486504
Hyperthermia malignant	93.05	40.40	16	1329	818	63486859
Bradycardia	85.59	40.40	38	1307	73189	63414488
Neuromuscular block prolonged	85.57	40.40	14	1331	528	63487149
Serotonin syndrome	84.01	40.40	29	1316	28653	63459024
Cardiac arrest	77.09	40.40	38	1307	92507	63395170
Anaphylactic shock	65.72	40.40	23	1322	23610	63464067
Delayed recovery from anaesthesia	60.70	40.40	11	1334	760	63486917
Anaphylactic reaction	57.54	40.40	28	1317	66072	63421605
Bronchospasm	48.72	40.40	17	1328	17263	63470414
Vitamin K deficiency	46.07	40.40	8	1337	432	63487245
Drug interaction	43.39	40.40	37	1308	229094	63258583
Unwanted awareness during anaesthesia	41.22	40.40	7	1338	331	63487346
Respiratory depression	40.61	40.40	14	1331	13701	63473976

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	170.85	42.46	33	1086	2144	34953668
Anaphylactic shock	101.39	42.46	32	1087	15909	34939903
Seizure like phenomena	87.87	42.46	16	1103	748	34955064
Serotonin syndrome	78.86	42.46	28	1091	19905	34935907
Bronchospasm	65.91	42.46	21	1098	10710	34945102
Trigemino-cardiac reflex	56.60	42.46	9	1110	184	34955628
Neuromuscular block prolonged	48.02	42.46	9	1110	492	34955320
Anticholinergic syndrome	45.15	42.46	10	1109	1259	34954553
Delayed recovery from anaesthesia	43.81	42.46	9	1110	792	34955020

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	244.80	37.08	47	2567	2870	79738904
Serotonin syndrome	153.33	37.08	57	2557	44970	79696804
Anaphylactic shock	146.54	37.08	52	2562	35944	79705830
Neuromuscular block prolonged	127.18	37.08	23	2591	1007	79740767
Bronchospasm	105.25	37.08	37	2577	24822	79716952
Bradycardia	98.60	37.08	59	2555	135498	79606276
Delayed recovery from anaesthesia	98.11	37.08	20	2594	1653	79740121
Cardiac arrest	95.30	37.08	63	2551	172033	79569741
Post procedural complication	91.52	37.08	33	2581	23796	79717978
Procedural hypotension	83.00	37.08	18	2596	2005	79739769
Anaphylactic reaction	75.61	37.08	42	2572	83701	79658073
Seizure like phenomena	73.17	37.08	16	2598	1851	79739923
Trigemino-cardiac reflex	67.45	37.08	11	2603	258	79741516
Drug interaction	63.91	37.08	73	2541	415110	79326664
Anticholinergic syndrome	57.79	37.08	15	2599	3596	79738178
Circulatory collapse	57.66	37.08	27	2587	37641	79704133
Hypotension	55.56	37.08	70	2544	440247	79301527
Recurrence of neuromuscular blockade	51.85	37.08	9	2605	310	79741464
Laryngospasm	51.57	37.08	14	2600	3983	79737791
Vitamin K deficiency	38.56	37.08	8	2606	720	79741054
Unwanted awareness during anaesthesia	38.41	37.08	7	2607	319	79741455
End-tidal CO2 increased	38.20	37.08	5	2609	22	79741752
Procedural vomiting	37.89	37.08	8	2606	783	79740991
Procedural nausea	37.39	37.08	8	2606	835	79740939

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01AB07	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons
CHEBI has role	CHEBI:38870	inhalation anesthetics
MeSH PA	D000777	Anesthetics
MeSH PA	D018685	Anesthetics, Inhalation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
FDA EPC	N0000175681	General Anesthetic
FDA PE	N0000175975	General Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Hyperkalemia	contraindication	14140009
Cirrhosis of liver	contraindication	19943007	DOID:5082
Viral hepatitis C	contraindication	50711007	DOID:1883
Viral hepatitis type B	contraindication	66071002	DOID:2043
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Myasthenia gravis	contraindication	91637004	DOID:437
Disease of liver	contraindication	235856003	DOID:409
Neuromyopathy	contraindication	255522009	DOID:440
Familial periodic paralysis	contraindication	267607008	DOID:1029
Lesion of brain	contraindication	301766008
Malignant hyperthermia	contraindication	405501007
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Bioact source	MoA source
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 3	Ion channel	O14649	KCNK3_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 9	Ion channel	Q9NPC2	KCNK9_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 10	Ion channel	P57789	KCNKA_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 18	Ion channel	Q7Z418	KCNKI_HUMAN	OPENER	CHEMBL	CHEMBL
Glycine receptor (alpha-1/beta)	Ion channel	P23415 P48167	GLRA1_HUMAN GLRB_HUMAN	POSITIVE MODULATOR	CHEMBL	CHEMBL
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRP_HUMAN GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRE_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN GBRT_HUMAN	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	CHEMBL

External reference:

ID	Source
4020649	VUID
N0000148295	NUI
D00546	KEGG_DRUG
27340	RXNORM
4020649	VANDF
C0063252	UMLSCUI
CHEBI:4445	CHEBI
DSF	PDB_CHEM_ID
CHEMBL1200733	ChEMBL_ID
DB01189	DRUGBANK_ID
D000077335	MESH_DESCRIPTOR_UI
42113	PUBCHEM_CID
6505	INN_ID
7156	IUPHAR_LIGAND_ID
CRS35BZ94Q	UNII
247482	MMSL
4545	MMSL
d02374	MMSL
004114	NDDF
108393001	SNOMEDCT_US
386841003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9961	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	24 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9961	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	24 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6172	LIQUID	240 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6172	LIQUID	240 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	10019-644	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	28 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	10019-644	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	28 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	10019-644	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	28 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-646	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	27 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-646	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	27 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-646	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	27 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	52584-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	23 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	52584-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	23 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	66794-021	LIQUID	250 mL	RESPIRATORY (INHALATION)	unapproved drug other	18 sections